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Homozygous mutations in the GBA gene encoding the 
lysosomal enzyme glucocerebrosidase (GCase) cause 
Gaucher disease (GD), the most common lysosomal  
 
storage disorder (LSD). GBA mutations are also 
numerically the most important known genetic risk 
factor for Parkinson disease (PD) [6, 39]. The most 
frequent GBA mutation associated with PD is N370S 
(N370SGBA) [6, 39]. Mutations in GBA decrease GCase 
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Glucocerebrosidase (GBA) mutations are the most important genetic risk factor for the development of Parkinson 
disease (PD). GBA encodes the lysosomal enzyme glucocerebrosidase (GCase). Loss-of-GCase activity in cellular 
models has implicated lysosomal and mitochondrial dysfunction in PD disease pathogenesis, although the exact 
mechanisms remain unclear. We hypothesize that GBA mutations impair mitochondria quality control in a 
neurosphere model.  
We have characterized mitochondrial content, mitochondrial function and macroautophagy flux in 3D-
neurosphere-model derived from neural crest stem cells containing heterozygous and homozygous N370SGBA 
mutations, under carbonyl cyanide-m-chlorophenyl-hydrazine (CCCP)- induced mitophagy. 
Our findings on mitochondrial markers and ATP levels indicate that mitochondrial accumulation occurs in mutant 
N370SGBA neurospheres under basal conditions, and clearance of depolarised mitochondria is impaired following 
CCCP-treatment. A significant increase in TFEB-mRNA levels, the master regulator of lysosomal and autophagy 
genes, may explain an unchanged macroautophagy flux in N370SGBA neurospheres. PGC1α-mRNA levels were also 
significantly increased following CCCP-treatment in heterozygote, but not homozygote neurospheres, and might 
contribute to the increased mitochondrial content seen in cells with this genotype, probably as a compensatory 
mechanism that is absent in homozygous lines.  
Mitochondrial impairment occurs early in the development of GCase-deficient neurons. Furthermore, impaired 
turnover of depolarised mitochondria is associated with early mitochondrial dysfunction. 
In summary, the presence of GBA mutation may be associated with higher levels of mitochondrial content in 
homozygous lines and lower clearance of damaged mitochondria in our neurosphere model. 
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activity, leading to defects in autophagic-lysosomal 
function and a-synuclein aggregate accumulation. 
 
Cell models of dermal fibroblasts or transformed 
lymphocytes (lymphoblasts) have been used to 
understand the cell biology associated with 
neurodegenerative diseases, including PD [10, 19, 41] 
but the utility of non-neural cells to provide insight into 
the cellular basis of neurodegeneration is limited [22]. 
The development of stem cell-derived models of 
disease, such as embryonic stem cells [13, 20] and 
induced pluripotent stem cells (iPSCs) from patients 
with PD are considered more appropriate in this respect 
[33]. Collections of neural stem cells, also known as 
neurospheres, have been developed from patients with 
neurodegenerative diseases, including PD [21, 28, 31]. 
Neurospheres have been used as a tool to model 
neurodegenerative disorders [21], developmental 
studies [1, 32], cell differentiation [47] and regenerative 
medicine [23]. Neural stem cell derived neurospheres 
have an advantage over embryonic/iPSCs, as they do 
not require genetic reprogramming. Neurospheres can 
be obtained by using pluripotent neural crest stem cells 
(NcSC) from adipose tissue [33, 43] and have been 
previously used in PD research [14].  
 
Mitochondrial dysfunction has been associated with 
aging and several neurodegenerative diseases including 
PD [35, 36], and several lines of investigation are 
directed towards increasing mitochondrial biogenesis and 
respiration as neuroprotective strategies [3]. 
Mitochondrial autophagy (mitophagy) has been shown to 
contribute to the pathogenesis of genetic forms of PD 
[15]. Mutations in genes that regulate mitophagy, such as 
PTEN-induced-putative-protein-kinase 1 (PINK1) and 
PARK2/Parkin-mutations cause early onset PD [25]. 
Following a loss of mitochondrial membrane potential 
(MMP) (↓ΔΨm), PINK1 accumulation in the outer 
membrane acts as a sensor for mitochondrial damage and 
induces translocation of cytosolic Parkin, through a 
mechanism that requires the kinase activity of PINK1 
[25]. Parkin ubiquitinates several mitochondrial proteins 
which aids the recruitment of damaged mitochondria to 
phagophores by binding to LC3-II directly, or via the 
adaptor protein p62 [45]. It is not clear whether p62 is 
required for Parkin mediated mitophagy [8, 24]. An 
increasing body of evidence implicates defects in quality 
control pathways in both GD and PD, but the precise role 
of mitochondrial function and mitophagy in the 
pathogenesis of these diseases remains to be elucidated 
[5, 7, 26, 37]. Transcription factor EB (TFEB) regulates 
autophagy by activating the genes that encode lysosomal 
hydrolases, lysosomal v-ATPase pumps, lysosomal 
regulators and autophagy regulators and so it is 
considered a master regulator of autophagy that has 
emerged as a potential therapeutic target for PD. TFEB 
has also been associated with activation of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α), a regulator of mitochondrial biogenesis. It has 
been reported that cells with increased TFEB protein 
have significantly higher PGC1α mRNA levels, resulting 
in increased mitochondrial content. These findings 
suggest that TFEB is activated following mitophagy to 
maintain the autophagy-lysosome pathway and 
mitochondrial biogenesis [11].  
 
The characterization of mitochondrial function and 
autophagy in neurospheres would help to clarify whether 
a cause-effect relationship between the presence of GBA 
mutations and mitochondrial dysfunction occurs before 
neuronal differentiation. We hypothesise that GBA 
mutations likely impair the clearance of damaged 
mitochondria, promoting their accumulation, as a result 
of abnormal autophagy flux processing or biogenesis. 
 
Mitophagy pathways could be altered in N370SGBA 
carriers due to defective recycling machinery and 
thereby changes in mitochondrial content. Therefore we 
have investigated the effect of N370SGBA mutations on 
macroautophagy and mitochondrial function in a 3D-
neurosphere model derived from NcSC, in either basal 





Homozygous, heterozygous and control donor subjects 
were age and sex matched, (Supplementary Table 1). 
 
Characterization of the neurosphere model 
 
We first followed the morphological changes of NcSC 
upon induction to neurospheres. Cell aggregates began 
to form within 24 hours and the spherical structures 
grew in size as time progressed (48, 72 and 96 hrs). 
(Supplementary Figure 1). 
 
Next, we measured the protein level of neuronal 
markers i.e. β-III tubulin and Microtubule-associated 
protein 2 (MAP2) (Figure 1A and 1B), and the mRNA 
level of the stem marker nestin (Figure 1C), as well as 
GCase, HEX and β-gal enzymatic activities (Figure 2) 
of the 6 lines over time, to identify the length of time 
taken for the neurospheres to become biochemically 
stable, and to compare the influence of N370SGBA 
zygosity on neurosphere formation. We chose 4 days 
as the duration for the studies as MAP2 and β-III 
tubulin were stable at this time and nestin levels were 
not significantly different between the lines. 
Quantification of GBA protein levels are shown in 
Supplementary Figure 4 GCase activity showed a 
trend to reduction by 33% (p=NS) in wt/N370SGBA and 
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was 98% decreased (p=0.049) in N370SGBA/N370SGBA 
when compared to controls, when measured at pH 5.4 
in the presence of sodium taurocholate. As a 
confirmation, measurement of GCase at pH 4.5 in the 
absence of the GCase activator sodium taurocholate 
yielded similar results, while HEX and β-gal were 
unaffected.  
 
Validation of uncoupler treatment to dissipate ΔΨ 
and to induce mitophagy in the neurosphere model 
 
Mitochondrial depolarisation following mitochondrial 
uncoupling was confirmed by loss of the long isoform 
of optic atrophy protein 1 (OPA1) (L-OPA1; Figure 3A 
and 3B) as previously described [9, 17, 30, 40] and was 
similar in all three genotypes. Mitochondrial content as 
measured by TOM20 protein level was decreased in a 
control cell line during the 24h CCCP treatment (Figure 
3C); the progressive response over the time of treatment 
confirms the effect of CCCP-induced depolarization.  
 
Mitochondrial content following mitophagy 
induction in mutant GBA neurospheres 
 
We compared the steady-state levels of mitochondrial 
content between different genotypes. As shown in 
Figure 4A, there was a significant increase in the levels 
of succinate dehydrogenase complex subunit A 
(SDHA), and a non-significant increase for voltage- 
dependent anion-selective channel 1 (VDAC) or 





Figure 1. Characterization of neurosphere development by analysis of β-III tubulin, MAP2 and nestin markers. Neuronal 
markers β-III tubulin and MAP2 were determined by Western Blot (A). Both neural markers showed stabilized expression on day 4 of 
development. β-III tubulin and MAP2 levels confirmed neural properties of neurospheres (B). Increasing nestin mRNA levels confirmed neural 
stem cell properties of neurospheres during development (C). No significant differences were found at 4 day of development AU, arbitrary 
units. Results are expressed by mean± SEM.  
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Figure 2. GCase, HEX and β-gal enzymatic activities stabilized from 0 to 6 days of differentiation. GCase activity decreased as 
expected for the respective genotypes (33% decrease in wt/N370SGBA and 98% decrease in N370SGBA/N370SGBA) when measured at pH 5.4 in 
the presence of sodium taurocholate. Measurement of GCase at pH 4.5 in the absence of the GCase activator sodium taurocholate yielded 




Figure 3. Confirmation of mitochondrial uncoupling with CCCP in the neurosphere model. Representative blots of OPA1 isoforms. 
Expected changes from long to short OPA1 isoforms were observed upon uncoupler treatment in all the genotypes, as mitochondria undergo 
depolarisation/fission following mitochondrial uncoupling (24h, 10 µM CCCP) (A and B). TOM20 levels progressively decrease from 0 to 24h in 
a control line (C). L-OPA1, long isoform of optic atrophy 1 protein OPA1; S-OPA1, short isoform of OPA1; UT, untreated.  
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As expected, trends to a reduction of protein level in a 
panel of mitochondrial markers representing the outer, 
inner membrane or mitochondrial matrix i.e VDAC1, 
SDHA and TFAM were present upon uncoupler 
treatment in the control lines (wt/wt) (Figure 4B) and 
ATP levels also decreased (Figure 4C). Despite the 
increase of mitochondrial content (SDHA subunit) 
under basal conditions, steady state levels of ATP in 
N370SGBA/N370SGBA presented trends to lower levels than 
control cells suggesting mitochondrial dysfunction 
(Figure 4C). After uncoupler treatment, ATP levels also 




Figure 4. Mitochondrial content under basal conditions in control, wt/ N370SGBA and N370SGBA/N370SGBA neurospheres was 
assessed by western blotting for the mitochondrial proteins VDAC1 (outer mitochondrial membrane), SDHA (inner 
mitochondrial membrane), and TFAM (matrix), normalized by β-actin content. All markers tended to increase in N370SGBA/N370SGBA 
neurospheres in basal conditions, when compared to control lines (A) (SDHA was significant). As expected in control lines, protein levels of 
VDAC1, SDHA and TFAM and ATP levels decreased following CCCP treatment for 24 hours (B and C). Despite an apparent increase in 
mitochondrial mass in untreated conditions, ATP levels remained unchanged in wt/N370SGBA and N370SGBA/N370SGBA neurospheres (C). 
Mitochondrial markers of wt/N370SGBA did not show a marked response to CCCP uncoupling, in fact, TFAM significantly increased in the 
heterozygous lines and the decrease in ATP levels were not so pronounced (B and C) and ATP levels of homozygous N370SGBA/N370SGBA 
neurospheres showed a null response to CCCP uncoupling. All of the above data suggest that mitochondrial function may be impaired in GBA 
mutant neurospheres. AU: arbitrary units. Thin line indicates p value <0.05. Results are expressed by mean± SEM. 
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mitochondrial markers were not so evident in 
wt/N370SGBA heterozygous lines and the response of 
ATP levels upon induced mitophagy was either partial 
or not observed in the wt/N370SGBA heterozygous and 
homozygous N370SGBA neurospheres, respectively. In 
fact, in the heterozygous line, the mitochondrial marker 
TFAM was significantly increased (Figure 4B). 
 
Since mitochondrial content is not only maintained by 
mitochondrial turnover but also mitochondrial biogenesis, 
we examined the latter by measuring mRNA levels of 
PGC1α transcript and one of its upstream regulators 
TFEB [11, 38] in neurospheres untreated and treated with 
CCCP for 24 hours. As displayed in Figure 5, 
mitochondrial depolarization led to a substantial and 
significant increase in PGC1α transcript in the 
heterozygous line compared to the control and 
homozygous lines. The steady-state level of TFEB mRNA 
expression was found inversely proportional to the GCase 
level, although not significantly (Figures 2 and 5). 
Treatment of wt/N370GBA or N370SGBA/N370SGBA 
neurospheres with CCCP resulted in similar TFEB 
mRNA levels, compared to control. PINK1 mRNA levels 
were similar in all the cell lines (data not shown) 
suggesting if there is impaired mitophagy it is probably 
not due to lower PINK1 levels (wt/wt 0.068±0.006, 
wt/N370SGBA 0.086±0.010, N370SGBA/N370SGBA 
0.058±0.059). 
 
Macroautophagy in neurospheres carrying N370SGBA 
mutation 
 
To investigate if mitophagy was impaired in 
neurospheres with GCase deficiency, we measured 
macroautophagy flux by LC3-II levels, a marker of 
autophagosome number, and sequestrosome/p62 (p62) 
levels (which helps bind both cargo and LC3-II in 
autophagosomes). Under basal conditions, p62 and 
LC3-II levels were similar in all groups (Figure 6). 
Following bafilomycin A1 (BAF) treatment, which 
prevents the fusion of autophagosomes to lysosomes, 
p62 and LC3-II increased in all groups as expected 
(Figure 6). However, there was no significant difference 
between the groups treated with BAF, suggesting that 
macroautophagy flux is not noticeably affected, which 
is in line with similar synuclein protein levels observed 
at day 4 of development (Supplementary Figure 3). 
 
A summary of the raw data obtained from the 




In this study neurospheres have been used to explore 
mitochondrial content, function and macroautophagy in 
the context of GBA mutations. 
 
Mitochondrial abnormalities have been associated with 
GBA mutations [6, 12, 26, 42], and recent data have also 
shown that mitochondrial dysfunction is present in post-
mortem tissues of PD patients, cell and animal models 
with the L444P GBA mutation [16]. Our study was 
designed to monitor steady-state levels of mitochondrial 
content, alterations in content upon mitochondrial 
depolarization induced mitophagy; the latter validated 
by loss of Ψm, decreased mitochondrial proteins, a 





Figure 5. Steady-state mRNA levels of TFEB and PGC1α during uncoupling treatment. TFEB mRNA levels tended to decrease in 
wt/N370SGBA, and N370SGBA/N370SGBA but PGC1α significantly increased upon CCCP induction in wt/N370SGBA, probably in an attempt to 
compensate for the underlying mitochondrial defects. UT, untreated. AU: arbitrary units. Thin line indicates p value <0.05. Results are 
expressed by mean± SEM. 
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Our data indicate that heterozygous and homozygous 
N370SGBA produced different patterns of modified 
mitochondrial content. Homozygous GBA mutations 
tended to increase mitochondrial content under basal 
conditions (significantly increased SDHA levels were 
observed), while uncoupling resulted in decreased 
clearance of mitochondrial content. Intriguingly, 
heterozygous GBA mutations tended to increase 
mitochondrial content following mitochondrial 
uncoupling, and this was coincident with a large increase 
in PGC1α mRNA levels, a master regulator of 
mitochondrial biogenesis. This could be a compensatory 
mechanism for heterozygous lines, which homozygous 
lines under the same insult are not able to perform. Our 
macroautophagy flux data did not indicate a significant 
problem with the formation of autophagosomes with 
lysosomes in mutant neurospheres, suggesting that, if 
mitophagy is impaired in these cells, it could be due to 
excessive mitochondrial biogenesis, as observed by the 
PGC1α increase [2], rather than the autophagic machinery 
required for the degradation of damaged mitochondria. 
However, it is possible that we have not been able to 
detect macroautophagy defects due to the low sample 
size. Nevertheless, the fact that macroautophagy is not 
noticeably affected is consistent with the absence of 
differences in synuclein levels at day 4 of neurosphere 
development. The association of the loss of GCase 
activity and an increase in synuclein levels has been 
consistently observed and, in our model homozygous 
lines showed trends to higher levels of synuclein, while 
heterozygous lines showed intermediate levels over the 
controls, at several points of their development. 
Mitochondrial fission, as measured by the disappearance 
of the long isoform of OPA1, was similar between lines, 
suggesting additional alterations of mitochondrial 
turnover. PINK1 mRNA levels were also similar, and we 
were unable to detect either endogenous PINK1 or parkin 
protein levels (data not shown) suggesting either 
PINK1/parkin mitophagy occurs at an undetectable rate in 
our model, or does not occur at all in neurospheres, 
although we cannot discard technical reasons underlying 
the lack of the detection of these proteins. Mitochondria in 
GBA KO mice cortical neurons have been shown to 
recruit GFP-tagged parkin upon depolarization to a 
similar level as controls [27]. Other mitophagy initiators 
[4, 46] might be required for mitophagy in neurospheres. 
For instance, other proteins related to mitophagy such as 
BNIP3, FUND1, SMURF1 and BCL2-L-13 could also be 
affected but are beyond the scope of this study. 
 
GCase deficiency in neuronal models is typically 
associated with an impairment of macroautophagy flux 
[5, 18, 37]. The increased mRNA levels of TFEB, a 
master regulator of lysosomal and autophagy genes [34] 
is the most likely explanation why we do not see 




Figure 6. Autophagy flux measurement. Macroautophagy flux showed trends to further increase in the control lines. p62 and LC3-2 
levels are similar in the 3 untreated cell lines, however, when autophagy was blocked under bafilomycin treatment, p62 and LC3-2 levels 
tended to increase the most in controls. The lack of significant differences suggests that preexistent mitochondrial impairment may account 
for the pathogenesis of GBA mutant neurospheres. AU, arbitrary units; UT, untreated; BAF, bafilomycin. Results are expressed by mean± 
SEM. 
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unable to maintain this compensatory mechanism, as 
they develop, particularly if mitochondrial dysfunction 
is occurring in these cells, and changes in autophagy 
flux are observed in more mature neurons. 
 
In summary, as illustrated in Figure 7, dysfunctional 
mitochondrial accumulation occurs in mutant GBA 
neurospheres under basal conditions. Our data suggest 
that the impaired turnover of depolarized mitochondria 
is not a result of impaired autophagosome formation 
and degradation, but has its origin at an early stage, 




Neurospheres are a suitable model to study lysosomal 
storage disorders. We show that mitochondrial 
dysfunction is an early event preceding macroautophagy 
flux, at least in this model of neurospheres containing 
pathogenic GBA mutations. 
 
Neurospheres might also be considered as a potential 




Figure 7. Global summary of the observed molecular 
parameters in GBA mutant neurospheres. Compared to the 
controls, dysfunctional mitochondrial accumulation occurs in 
mutant GBA neurospheres under basal conditions, as shown by 
the accumulation of healthy and altered mitochondria, 
represented as elongated and rounded structures, respectively. 
Mitochondrial elimination is correct under mitophagy induction 
(CCCP) in the control line, as observed by the decrease of ATP, 
represented by the battery, and the macroautophagy induction, 
represented by the garbage bin. There is an impaired turnover of 
depolarized mitochondria under induced mitophagy in GBA 
neurospheres. This is not a result of impaired autophagosome 
formation and degradation, but at an earlier stage, where 
defective mitochondrial dysfunction was observed. 
because these cells can proliferate and differentiate into 
new neurons, astrocytes, and oligodendrocytes [14]. 
 




All patients and controls included in the study signed an 
informed consent. The study has been approved by the 
institutional ethics committee Royal Free Research 
Ethics Committee (REC number 10/H0720/21). 
Methods have been performed in accordance with the 
appropriate guidelines and regulations of University 
College of London. 
 
Cell culture and treatment 
 
Neural crest stem cells were obtained as previously 
described [44]. 6 cell lines corresponding to 
homozygous (N370SGBA/N370SGBA, n=2), heterozygous 
(wt/N370SGBA n=2) and control (wt/wt, n=2) subjects 
were grown in DMEM media supplemented with 10% 
fetal bovine serum, 1mM pyruvate, 0.5 ml uridine 
(50mg/ml) and 0.5% penicillin-streptomycin-fungizone. 
Then, cells were detached with accutase and cultured in 
DMEM-F12 (1:1) containing the following supplements 
and growth factors, 1x B27, 20μL leukemia inhibitor 
(10ng/mL), basic fibroblast growth factor (40ng/mL 
FGF2), epidermal growth factor (10ng/mL EGF) and 
1% penicillin-streptomycin-fungizone.  
 
Mitochondrial depolarization-mediated mitophagy was 
induced for 24 hours with 10 µM CCCP. Bafilomycin 
treatment was performed for 4 hours at 0.5 µM. Cells 
were washed twice with phosphate-buffered saline 
(PBS) and collected for analysis as described below. 
 
Western blot analysis and densitometry 
 
Neurospheres were lysed and placed on ice for 15 min 
with RIPA buffer supplemented with 1x Halt protease 
inhibitor cocktail (Pierce). Cell lysates were centrifuged 
at 21,000g at 4°C for 5min and soluble material was 
retained for Western Blot analysis. 
 
Protein levels were determined by using a bicinchoninic 
acid (BCA) kit (Pierce Thermo Fisher; Basingstoke, UK). 
 
Equal amounts of 20 µg protein from the soluble 
material were resolved under reducing conditions in 
either: i) NuPAGE 4–12% polyacrylamide precast gels 
(Invitrogen, Carlsbad, CA, USA) using the 2 (N 
morpholino) ethane sulphonic acid (MES) buffer or: ii) 
NuPAGE 12% (Invitrogen, Carlsbad, CA, USA) using 
MOPS buffer and transferred onto Immobilon 
polyvinylidene difluoride membrane (PVDF) 
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(Millipore, Watford, UK). Blocking was made with 
10% skimmed milk powder in PBS. Antibodies 
detecting microtubule associated protein 2 (MAP2) 
(1:1000 MAP2, Invitrogen), βIII tubulin (1:1000 
ab7751 Abcam), p62 (1:1666 ab56416 Abcam), β actin 
(1:10000, Sigma), TFAM (1:1000 Thermo Fischer 
Scientific), TOM20 (1:1000 Santa Cruz), VDAC1 
(1:1000 ab14734 Abcam), SDHA (1:1000 ab14715 
Abcam), OPA1 (1:500 BD/612606) and LC3 (1:1000 
Cell Signalling) were used. Horseradish peroxidase 
conjugated secondary antibodies against mouse and 
rabbit IgG were used (1:2000) (Dako, Glostrup, 
Denmark). ECL reagent (GE Healthcare, Bucks, UK) 
was used to develop the blots and signals detected 
through the Chemidoc MP System (BioRad) and band 
densities measured using ImageLab analysis software. 
Data were normalized to β-actin levels.  
 
Lysosomal enzyme assays 
 
GCase, beta-hexosaminidase (HEX) and beta-
galactosidase (β-gal) enzymatic activities were 
determined at 37 °C. CE-sensitive GCase activity (end-
point measurement) was determined as described [29] at 
pH 5.4 using 4-methylumbelliferyl-β-d-glucopyranoside 
as substrate in a plate reader and its activity is reported 
in the presence of the activator sodium taurocholate 
(Sigma). The increase in fluorescence of released 4-
methylumbelliferone at 460 nm following excitation at 
360 nm was followed after 1 h (Synergy, LabTech; 
Brighton, UK). Total HEX and β-gal were assayed with 
4-methylumbelliferyl-2-acetoamido-2-deoxy-6-sulpho-
b-D-glucopyransoside and 4-methylumbelliferyl-B-D-
galactopyranoside as substrates, respectively. 
Enzymatic activities were normalised to the amount of 
proteins of the samples. Results were expressed as 
nmol/hour or minute/mg protein. A full length blot is 




ATP Bioluminescence was measured in a microplate by 
the ATP Bioluminescence Assay Kit CLS II (Roche), 
following manufacturer’s instructions. Briefly, different 
dilutions of samples and serial diluted ATP standards 
were included as an internal curve in a black opaque 
microplate. Then a volume of 50μl luciferase reagent was 
added and luminescence was immediately measured in a 
synergy device (Synergy, LabTech, Brighton, UK). ATP 
levels were normalised to the amount of total proteins of 
the samples. Results were expressed as pmol/mg protein. 
 
Levels of mRNA 
 
Following treatment, RNA was extracted from cells 
using RNeasy kit (Qiagen). RNA was converted to 
cDNA (Primer Design, Southampton, UK) and relative 
mRNA levels were measured using SYBERgreen 
(Applied Biosystems, Paisley, UK). Relative expression 
of Nestin (forward ACCAAGAGACATTCAGACTCC 
and reverse CCTCATCCTCATTTTCCACTCC), TFEB 
(forward CCAGAAGCGAGAGCTCACAGAT and 
reverse TGTGATTGTCTTTCTTCTGCCG, PGC1α 
(forward CAGAGAACAGAAACAGCAGCA and 
reverse TGGGGTCAGAGGAAGAGATAAA) and 
PINK1 (forward GGACGCTGTTCCTCGTTA and 
reverse ATCTGCGATCACCAGCCA). mRNA was 
measured with Power SYBRgreen kit (Applied 
Biosystems) using a STEP One PCR device (Applied 
Biosystems). GAPDH (forward GAAGGTGAAGGTC 
GGAGT and reverse GAAGATGGTGATGGGATT 
TC) mRNA levels were used to normalise data. Relative 




Low sample size only allowed us to use replicates for 
comparisons. One way ANOVA followed by 
Bonferroni’s post-hoc correction was performed using 
SPSS Version 20 and GraphPad Version 8 to assess 
whether differences between groups were present. 
Results were expressed as mean ± SEM and significance 




All patients and controls included in the present study 
have presented their informed consent and the study has 
been approved by the institutional ethics committee 
Royal Free Research Ethics Committee (REC number 
10/H0720/21). Methods have been performed in 
accordance with the appropriate guidelines and 
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Supplementary Figure 1. Neurosphere formation and morphology from neural crest stem cells to 4 days of development. 




Supplementary Figure 2. Full-length blot corresponding to cropped data on OPA-1, SDHA, p62, β-actin, VDAC, TFAM and LC3BI/II, showing 
different specific tested antibodies in the same blot (from the top to the bottom of the blot): OPA-1, SDHA, P62, β-actin, VDAC, TFAM, LC3b-
I/II…) represented in Figures 3, 4 and 6. Protein levels are quantified in each case before overexposure occurs.  
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Supplementary Figure 3. Synuclein protein levels during neurospheres development. Representative blots of synuclein protein 
expression levels during neurospheres development (A) and quantification of the protein expression levels (B).  There is no difference in a-
synuclein levels at 4 days, the time point where most experiments were conducted. 
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Supplementary Figure 4. (A). Representative blots and quantification of GBA protein levels in the control, homozygous and heterozygous 
lines. (B). Quantification of GBA protein levels over time in all the three genotypes.  
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Supplementary Tables 
 
Supplementary Table 1. Epidemiological data of the studied cohorts at the time of biopsy.  
GROUP N 
GENDER AGE 
MALE FEMALE RANGE MEAN SEM 
wt/wt 2 1 1 56-73 64.5 ±1.73 
wt/∆ 2 1 1 45-75 60 ±2.3 
(∆/∆) 2 1 1 58-76 67 ±1.78 
No significant differences were found in age or gender between groups. wt/wt: controls, wt/N370S heterozygous subjects for 
GBA mutation and N370S/N370S: homozygous patients with GBA mutation. N: Number of cases enrolled. SEM: Standard 
error of the mean. 
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Supplementary Table 2. Raw data of all the parameters measured.  
Raw data 
Parameter (units) 
wt/wt (n=2) wt/N370S (n=2) N370S/N370S (n=2)  






























O DOD 51,55 13,43 139,84 7,11 171,27 76,58 2,32 48,55 0,013 
2 DOD 95,32 71,73 315,15 71,54 230,62 174,05 83,21 82,60 0,262 
4 DOD 65,88 59,25 200,98 21,98 205,07 150,79 93,86 128,89 0,440 
6 DOD 75,73 66,91 236,28 55,15 212,00 145,21 128,56 91,74 0,524 
MAP2 
(AU) 
O DOD 373,98 229,95 122,12 4,40 - 67,35 210,60 56,24 - 43,69 0,502 
2 D OD 245,73 58,84 63,04 35,14 - 74,35 79,17 21,29 - 67,78 0,190 
4 DOD 49,42 9,56 0,63 0,35 - 98,73 0,79 0,21 - 98,40 0,716 
6 DOD 67,18 15,41 96,66 60,73 43,89 83,10 25,19 23,70 0,872 
Nestin 
(AU) 
O DOD 0,14 0,07 0,03 0,03 - 76,36 0,11 0,03 - 22,00 0,380 
2 D OD 1,00 0,42 0,97 0,19 - 2,99 1,06 0,52 5,21 0,380 
4 DOD 4,37 0,35 1,81 0,38 - 58,60 1,10 0,52 - 74,70 0,989 
























O DOD 384,00 4,00 167,00 22,00 - 56,51 0,50 1,50 - 99,87 0,001 
2 DOD 502,50 25,50 149,50 42,50 - 70,25 14,50 1,50 - 97,11 0,003 
4 DOD 355,00 83,00 239,00 65,00 - 32,68 - 6,50 0,50 - 101,83 0,053 





O DOD 46,50 21,50 11,00 5,00 - 76,34 8,50 0,50 - 81,72 0,207 
2 DOD 111,50 41,50 87,00 27,00 - 21,97 54,50 6,50 - 51,12 0,469 
4 DOD 145,00 52,00 86,50 9,50 - 40,34 6,50 1,50 - 95,52 0,469 
6 DOD 195,50 1,50 120,50 54,50 - 38,36 56,00 46,00 - 71,36 0,201 
HEX 
O DOD 66,50 23,50 71,50 15,50 7,52 56,50 3,50 - 15,04 0,816 
2 DOD 150,50 12,50 121,50 77,50 - 19,27 109,00 17,00 - 27,57 0,821 
ot) 
4 DOD 133,50 29,50 150,00 19,00 12,36 122,00 28,00 - 8,61 0,764 
6 DOD 234,00 31,00 177,00 2,75 - 24,36 209,50 99,50 - 10,47 0,810 
b-gal 
O DOD 292,00 73,00 340,50 20,50 16,61 192,50 19,50 - 34,08 0,207 
2 D OD 842,00 277,00 494,00 230,00 - 41,33 775,00 232,00 - 7,96 0,622 
ot) 
4 DOD 602,00 90,00 544,00 272,50 - 9,63 528,00 133,00 - 12,29 0,956 
























) VDAC-1/b- actin (AU) 
UT 258,64 29,63 73,96 18,69 - 71,41 338,34 88,81 30,82 0,088 
CCCP 144,48 53,99 138,43 21,85 - 4,19 251,18 58,51 73,85 0,311 
SDHA/b-actin 
(AU) 
UT 328,90 14,77 263,85 19,86 - 19,78 831,23 234,23 152,73 0,106 
CCCP 158,72 9,02 204,41 14,98 28,79 318,22 44,52 100,49 0,055 
TFAM/b-actin 
(AU) 
UT 116,13 1,94 120,46 0,73 3,73 240,93 172,55 107,47 0,647 

















0 HRS 0,01 0,01 0,01 0,00 - 29,34 0,01 0,01 - 21,32 0,052 
4 HRS 0,01 0,01 0,01 0,00 - 24,91 0,01 0,00 - 28,16 0,005 
16 HRS 0,00 0,00 0,00 0,00 66,68 0,01 0,00 190,40 0,001 




















UT 0,01 0,00 0,02 0,00 88,77 0,03 - 135,47 0,084 
CCCP 0,01 0,00 0,01 0,00 31,73 0,02 - 53,94 0,030 
PGC1D/GDA 
PH (AU) 
UT 0,08 0,00 0,12 0,00 49,71 0,11 - 40,87 0,014 

















UT 252,42 30,69 137,08 16,69 - 45,69 193,86 56,29 - 23,20 0,184 
BAF 924,84 555,57 602,24 149,36 - 34,88 887,29 145,28 - 4,06 0,776 
LC3B2/bACTI 
N (AU) 
UT 1.499,54 754,45 559,01 253,21 - 62,72 674,63 176,19 - 55,01 0,316 
BAF 4.385,22 1.404,53 2.624,67 949,57 - 40,15 3.193,41 364,23 - 27,18 0,446 
wt/wt: controls, wt/N370S heterozygous subjects for GBA mutation and N370S/N370S: homozygous patients with GBA 
mutation. DOD: days of differentiation, UT: untreated, BAF: bafilomycin. 
 
 
 
